View as cardsView as table
Fiscal Year Awarded Principal Investigator
A high-throughput platform for the non-invasive intracellular delivery of molecules for therapeutic applications
2020 Johan Paulsson
A kinase inhibitor for malignant brain tumors
2023 Timothy Mitchison
A natural beta interferon-inducing therapeutic glycolipid from the microbiome that prevents and treats severe viral infection
2022 Dennis Kasper
A novel biologic and therapeutic target for the treatment of diabetes
2021 Douglas Melton
A novel system for rational discovery of polycystic kidney disease therapeutics
2019 Adrian Salic
A platform for transcriptome time-series in single cells with applications to hematopoietic stem cells
2022 Johan Paulsson
Agents modulating B cell activation through the CD81-CD19 co-receptor complex
2023 Stephen Blacklow
Antibody-based therapeutics against Nipah virus
2023 Jonathan Abraham
Application of the SPLANDID antigen presentation technology to HIV-1 vaccine development
2021 James Chou
Assessment of targeted protein degradation as a strategy for potent antivirals with high barriers to resistance
2017 Priscilla Yang
Brain-penetrant kinase inhibitors targeting Alzheimer's and related dementias
2023 Mark Albers
Building better screens and identifying ligands for human MS4A proteins
2017 Sandeep Datta
CNS drug delivery by identifying small molecule inhibitors of a newly identified key regulator of the blood brain barrier
2022 Chenghua Gu
Computationally designed therapy targeting lysosomal function and inflammation in neurodegenerative diseases
2019 Peter Park
Design of novel protease inhibitors to enhance immune checkpoint blockade in cancer therapy
2024 Mark Namchuk
Developing a ubiquitin-dependent proteasome activity reporter to screen for activators and inhibitors
2017 Marc Kirschner
Developing CRISPR-Cas9 reagents for editing lytic and latent herpes simplex virus genomes
2018 David Knipe
Developing novel agonists of cytokine receptors by targeting receptor pre-clusters
2023 James Chou
Developing novel therapeutic approaches for CNS drug delivery by targeting a newly identified key regulator of the blood brain barrier
2020 Chenghua Gu
Developing therapeutics for treating Rett syndrome by correcting neuronal long-gene misregulation – Lead compound optimization and in vivo validation
2017 Michael Greenberg
Developing therapeutics for treating Rett Syndrome by correcting neuronal long-gene misregulation – Lead compound optimization and in vivo validation
2018 Michael Greenberg
Development of a new precision therapeutic for an important cancer target
2019 Stephen Blacklow
Development of a novel monoclonal antibody that targets SARS-CoV-2 3a
2022 John Mekalanos
Development of a synthetic promoter pipeline for safe and efficient gene therapy
2024 George Church
Development of AAV-mediated mini-gene therapy for Usher syndrome type 1F, a combined deafness and blindness
2019 David Corey
Development of an inexpensive at-home influenza kit and detection technology
2021 Michael Springer
Development of an inexpensive at-home influenza kit and detection technology
2019 Michael Springer
Development of new antiviral compounds
2019 Donald Coen
Development of novel AAV-mediated in vivo gene editing approaches to treat inherited collagen VI-related myopathies
2024 Amy Wagers
Development of small molecule modulators of autophagy and ER stress as novel therapeutics for AD
2018 Junying Yuan
Development of synthetic analogs of a sleeve gastrectomy-induced metabolite as a novel therapy for type 2 diabetes and obesity
2020 Abigail Devlin
Engineered proteins for treatment of pancreatitis
2020 Pamela Silver
Enzyme prospecting for better diagnostics
2022 Michael Springer
Evaluating antisense oligos for therapeutic impact in liver fibrosis and hepatocellular carcinoma
2023 Karen Adelman
Evaluating splicing modulators for therapeutic impact in cohesin-mutant AML and MDS cells
2020 Karen Adelman
Evaluating splicing modulators for therapeutic impact in cohesin-mutant AML and MDS cells
2021 Karen Adelman
Functional antibody screening with micro-capsules - proof of concept with anti-EGFR
2024 Allon Klein
Gene editing to treat hereditary deafness
2024 David Corey
Gene therapy for the treatment of Wolfram Syndrome II
2022 Amy Wagers
Identification of dengue virus inhibitors
2018 Priscilla Yang
Identification of druggable targets against Vibrio pathogens
2023 Norbert Perrimon
Identification of small molecule binders of the novel cancer immunotherapy target Bird33
2024 Arlene Sharpe
Identifying novel therapeutic targets for treating pain and chronic itch
2021 David Ginty
Interleukin-17 as a novel erythropoiesis stimulating agent
2020 Allon Klein
Isoguvacine and benzodiazepine derivatives for the treatment of tactile hypersensitivity and anxiety in autism spectrum disorders
2019 David Ginty
Manipulating mitobiogenesis by targeting ME2
2023 David Scadden
Methods and applications of semi-permeable capsules with current application to high-throughput single cell multi-omics
2023 Allon Klein
Microtubule stabilizing drugs for neurodegenerative disease and spinal cord injury
2017 Timothy Mitchison
Monoclonal antibody-based therapeutics for Argentine hemorrhagic fever
2020 Jonathan Abraham
Multimodal imaging and machine learning for diagnosis and patient stratification with predictive biomarkers
2024 Peter Sorger